Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders

Abstract The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morb...

Full description

Bibliographic Details
Main Authors: Paxton Bach, Daniel Hartung
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Addiction Science & Clinical Practice
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13722-019-0158-0
id doaj-b378a92dc3e64b24abec4d963f529a0c
record_format Article
spelling doaj-b378a92dc3e64b24abec4d963f529a0c2020-11-25T02:25:03ZengBMCAddiction Science & Clinical Practice1940-06402019-09-0114111110.1186/s13722-019-0158-0Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disordersPaxton Bach0Daniel Hartung1British Columbia Centre on Substance Use, University of British ColumbiaCollege of Pharmacy, Oregon State University/Oregon Health and Science UniversityAbstract The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.http://link.springer.com/article/10.1186/s13722-019-0158-0Community pharmacy servicesOpioid-related disordersOpiate substitution treatmentHarm reduction
collection DOAJ
language English
format Article
sources DOAJ
author Paxton Bach
Daniel Hartung
spellingShingle Paxton Bach
Daniel Hartung
Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
Addiction Science & Clinical Practice
Community pharmacy services
Opioid-related disorders
Opiate substitution treatment
Harm reduction
author_facet Paxton Bach
Daniel Hartung
author_sort Paxton Bach
title Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_short Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_full Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_fullStr Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_full_unstemmed Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
title_sort leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders
publisher BMC
series Addiction Science & Clinical Practice
issn 1940-0640
publishDate 2019-09-01
description Abstract The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.
topic Community pharmacy services
Opioid-related disorders
Opiate substitution treatment
Harm reduction
url http://link.springer.com/article/10.1186/s13722-019-0158-0
work_keys_str_mv AT paxtonbach leveragingtheroleofcommunitypharmacistsinthepreventionsurveillanceandtreatmentofopioidusedisorders
AT danielhartung leveragingtheroleofcommunitypharmacistsinthepreventionsurveillanceandtreatmentofopioidusedisorders
_version_ 1724853002261495808